



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶ : A61K 48/00 | A1 | (11) International Publication Number: WO 99/21591 (43) International Publication Date: 6 May 1999 (06.05.99) |
| (21) International Application Number: PCT/US98/22841 (22) International Filing Date: 28 October 1998 (28.10.98) (30) Priority Data: 60/063,360 28 October 1997 (28.10.97) US (71) Applicant (for all designated States except US): AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07840 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MUSUNURI, Shankar [IN/US]; 23 Lindenwood Drive, Exton, PA 19341 (US). SATISHCHANDRAN, C. [US/US]; 605 Shepard Drive, Lansdale, PA 19446 (US). (74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: COMPOSITIONS AND METHODS FOR DELIVERY OF GENETIC MATERIAL (57) Abstract A soluble ionic complex is formed by an aqueous mixture of a benzylammonium group-containing surfactant and a polynucleic acid sequence. When the mixture forms a vesicular complex, the sequence is packaged therein. This composition is useful in pharmaceutical compositions and in methods of delivering the polynucleic acid sequence (which preferably encodes a protein or peptide) to a cell for expression. Such methods are useful in therapy, as vaccines and as gene therapy agents. | | |

BEST AVAILABLE COPY

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

COMPOSITIONS AND METHODS FOR DELIVERY OF GENETIC MATERIAL

Field of the Invention

The present invention relates to compositions and methods for introducing
5 genetic material into cells. More particularly, the present invention relates to
compositions and methods for *in vitro* and *in vivo* gene transfer, which can be used to
deliver protective and/or therapeutic agents including genetic material that encodes
protein targets for immunization and therapeutic proteins.

10 Background of the Invention

The direct introduction of a normal, functional gene into a living animal has
been studied as a means for replacing defective genetic information. DNA can be
introduced directly into cells of a living animal using viral vectors, liposomes, lipid
complexes, ligand/DNA conjugates, and microprojectile bombardment, among other
15 methods. Various methods and compositions for mediating transfer of DNA to cells *in*
vivo and/or *in vitro* are referred to in U. S. Patent No. 5,593,972, issued January 14,
1997; U. S. Patent No. 5,580,859, issued December 3, 1996; U. S. Patent No.
5,589,466 issued December 31, 1996; U. S. Patent No. 5,676,954, issued November
19, 1996; International Patent Publications Nos. WO90/11092, published March 21,
20 1990; WO93/17706, published March 10, 1993; WO93/23552, published May 21,
1993; and WO94/16737, published January 26, 1994, and the priority applications
cited therein.

Despite the knowledge extant in the art, there remains a need for improved
methods of DNA transfer, as well as for improved methods and compositions for *in*
25 *vivo* and *in vitro* nucleic acid transfer. There remains a need for improved methods of
drug delivery.

Summary of the Invention

In one aspect, the invention provides soluble, ionic complex comprising an aqueous mixture of a benzylammonium group-containing surfactant and a polynucleic acid sequence. In one embodiment, the complex is a vesicular-like or liposomal-like complex comprising an aqueous mixture of a benzylammonium group-containing surfactant of the formula described herein and a polynucleic acid sequence, with the sequence substantially packaged in the vesicular complex.

In another aspect, the invention provides a mixture of multiple ionic and/or vesicular complexes of uniform size, as above described. In one embodiment, the composition is formed by mixing an aqueous solution of a benzylammonium-containing surfactant, preferably benzalkonium chloride, with a polynucleic acid sequence.

In still another aspect, the invention provides a pharmaceutical composition comprising at least one, and preferably multiple ionic complexes or vesicular complexes described above and a suitable pharmaceutical carrier.

In yet another aspect, the invention provides a method of introducing a polynucleic acid sequence into a cell comprising the step of contacting said cell with the above described complexes or compositions containing them.

In another aspect, the invention provides a method of facilitating the uptake of a polynucleic acid sequence into a cell comprising contacting the cell with a soluble ionic complex described above, or with a polynucleic acid substantially packaged in a vesicular complex formed by an aqueous mixture of a benzylammonium-containing surfactant with the polynucleic acid sequence.

In a further aspect, the invention provides methods of inducing an immune response in a mammalian or vertebrate subject to a pathogenic antigen or disease, which methods include the step of administering to cells of said subject, an effective amount of a complex as described herein, wherein the polynucleic acid sequence encodes at least one epitope that is identical or substantially similar to an epitope of a antigen of said pathogen, or a sequence encoding a target protein, said protein comprising an epitope identical or substantially similar to an epitope of a protein associated with cells that characterize said disease. The epitope or protein-encoding

sequence is under the control of regulatory sequences that direct expression of said protein in the cells of said subject.

In still another aspect, the invention provides a method of treating a mammalian or vertebrate subject for a disease comprising the step of administering to cells of said subject, an effective amount of a composition comprising a complex of this invention
5 formed by an aqueous mixture of a benzylammonium-containing surfactant and a polynucleic acid sequence, wherein said polynucleic acid sequence comprises a sequence which encodes a protein that produces a therapeutic effect on the subject or a protein that compensates for a missing, non-functional or partially functioning native mammalian protein, the protein-encoding sequence under the control of regulatory
10 sequences that direct expression of said protein in the cells of said subject.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

Brief Description of the Drawings

15 Fig. 1 is a bar graph showing the humoral (antibody) response measured in optical density (OD) at 450 nm in serum of individual Balb/C mice to an aqueous composition of the invention containing the indicated concentrations of benzalkonium chloride and indicated amounts of a DNA plasmid encoding the gD₂ protein of Herpes Simplex Virus as measured by standard ELISA. The positive and negative controls are
20 the same plasmid with no transfection facilitating agent (DNA only) and the plasmid with no gD₂ encoding sequence with no transfection facilitating agent (023ctrl). Each bar represents a single animal. See Example 4 below.

Fig. 2 is a bar graph showing group average humoral (antibody) responses in the animals of Fig. 1. The responses are measured according to Antibody Response
25 Calculations in ng/ml, as defined in Example 4 below.

Fig. 3 is a scatter plot graph showing the individual (animals represented by ◇, □, △, X, and *) and group average (represented by •) cellular responses of the animals of Fig. 1. Systemic cellular response (SI) was measured using a splenic cell proliferation assay.

Detailed Description of the Invention


The present invention provides a novel soluble ionic complex comprising an aqueous mixture of a benzylammonium group-containing surfactant; and a polynucleic acid sequence. These soluble complexes may be in the form of vesicular complexes containing polynucleic acid sequences substantially packaged therein. Compositions containing the complexes are useful as pharmaceutical (therapeutic and vaccinal) agents and as gene therapy reagents in methods for introducing the polynucleic acid sequences into a cell for a variety of therapeutic and prophylactic purposes, as well as for research purposes. The compositions and methods of the present invention provide for a high level of uptake and function of the polynucleic acid sequences and molecules.

I. The Soluble Ionic Complexes

A soluble ionic complex of this invention is formed by an aqueous mixture of a benzylammonium group-containing surfactant and a polynucleic acid sequence. The combination of the surfactant and the polynucleic acid sequence forms a vesicular-like or liposomal-like structure, in which substantially all of the polynucleic acid sequence becomes packaged. Minor amounts of the polynucleic acid sequence are associated with the exteriors of the vesicular complex. Without wishing to be bound by theory, these complexes appear to provide *in vivo* stability to the polynucleic acid sequences associated therewith, and thus facilitate transfection of such sequences into host cells.

A. The Surfactant

The benzylammonium group-containing surfactant is preferably a surfactant of the formula:



wherein X is an anion;

each R^1 is independently a hydrogen or a lower alkyl group comprising from 1 to 6 carbon atoms;

R^2 is CH_2 or $-O-$;

R^3 is H, CH_3 , C_2H_5 , phenyl, mono-substituted phenyl, or di-substituted phenyl, wherein said substitutions are independently selected from among
5 C_1 - C_{10} branched or straight chain alkyls groups; and

n is an integer of 2 through 7, provided that when n is 1, R^3 is methyl, ethyl, phenyl or substituted phenyl; when n is 4 through 6, R^3 is H, methyl, ethyl or phenyl; when n is 6, R^3 is H, methyl or ethyl; and when n is 7, R^3 is H or methyl.

10 Examples of preferred benzylammonium-group containing surfactants include those which comprise a dimethyl benzyl ammonium group linked to an alkyl group or an alkyl group linked to an aromatic group. The anion is selected from among anions that results in soluble complexes with the polynucleic acid sequence in water. In some embodiments, the anion is a halide, a sulfate, or a carbonate. In one
15 preferred embodiment, the anion in the surfactant is a halide, such as chloride. One of skill in the art may select from among a number of suitable anions for the preparation of a surfactant suitable for the present invention.

One presently preferred example of a benzylammonium group-containing surfactant is a benzalkonium halide, such as benzalkonium chloride.
20 Benzalkonium chloride is a cationic surfactant known to condense DNA [V. Jelen et al, Journal of Electroanalytical Chemistry, 377: 197-203 (1994)]. It has also been used as an antimicrobial agent for parenteral preparations [*Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field; and "Pharmaceutical Dosage Forms: Parenteral Medication", Vol.I, K. Avis et al (eds), Marcel Dekker, Inc., New
25 York (1992)]. Benzalkonium chloride refers to commercially available surfactants which are a mixture of alkyldimethylbenzylammonium chlorides of the formula above where $[CH_2CH_2R^2]_n-R^3$ is a mixture of alkyls C_8H_{17} to $C_{18}H_{37}$, i.e., n is 2-6, each R^2 is CH_2 and R^3 is hydrogen, methyl or ethyl. Benzalkonium chloride which may be used as the surfactant in the complexes, compositions, kits and methods of the invention

may be homogenous or may contain a mixture of compounds characterized by having two or more different R groups according to the formula above. Benzalkonium chloride, U.S.P. grade can be purchased from Spectrum Chemical Mfg. Corp., Gardena, CA.

Another exemplary surfactant useful in this invention is a benzethonium halide, such as benzethonium chloride. Benzethonium chloride refers to a commercially available surfactant N,N-dimethyl-N-[2-[2-[4 (1,1,3,3-tetramethylbutylphenoxy)ethoxy]ethyl]ammonium chloride, and is described in U. S. Patent Nos. 2,115,250, 2,170,111 and 2,229,024. It has also been used as an antimicrobial agent for parenteral preparations [Pharmaceutical Dosage Forms, cited above]. Benzethonium chloride has the formula set out above where n is 2 and R³ is 4-[1,1,3,3-tetra methylbutyl]phenyl. Benzethonium chloride, U.S.P. grade can be purchased from Spectrum Chemical Mfg. Corp., Gardena, CA.

The complexes of the present invention comprise a final concentration of benzylammonium-group containing surfactant between about 0.001 to about 2.4% by volume (w/v). Desirably, the complexes have a final concentration of the surfactant of between about 0.001-0.10% w/v. More preferably, the concentration of surfactant in the complexes is between about 0.005-0.06% w/v. A particularly desirable vesicular complex of this invention contains a benzylammonium-group containing surfactant in a concentration of between about 0.005 -0.03%w/v. Manipulation of the other components of the complex, e.g., the polynucleic acid, and the buffering agents and optional isotonicity and pH adjusting agents, can reduce the toxicity of the surfactant, and permit a soluble complex to be formed at a variety of concentrations of surfactant without encountering precipitation. One of skill in the art given the instructions provided herein is expected to be able to readily manipulate the components of this invention to provide such soluble complexes at a variety of surfactant concentrations.

B. The Polynucleic Acid Sequence

Another component of the complexes of the present invention is a polynucleic acid sequence, which when admixed with the above-described aqueous surfactant, forms a soluble ionic complex therewith. In preferred embodiments, the

polynucleic acid sequence becomes substantially packaged in the vesicular-like or liposomal-like complex, and only a minor amount of such polynucleic acid sequence is associated with the exterior of the complex.

The polynucleic acid sequences which form part of the complexes of this invention are preferably "dissociated from an infectious agent", i.e., are not part of a viral, bacterial or eukaryotic vector, either active, inactivated, living or dead, that is capable of infecting a cell. In some embodiments, the polynucleic acid sequence present in compositions of the present invention are preferably free from infectious agents such as viral particles, particularly retroviral particles, and are preferably non-infectious plasmid DNA molecules. In some preferred embodiments, the compositions are free of lipids, such as cationic lipids; and/or other surfactants, and/or local anaesthetics. In some embodiments, the polynucleic acid sequences are free from the precipitating agent CaPO_4 .

The complexes and compositions of the present invention preferably comprise between about 10 $\mu\text{g/ml}$ to about 20 mg/ml of polynucleic acid sequences or molecules. Preferably, the aqueous compositions of surfactant and polynucleic acid sequences which form the complexes of the invention comprises a concentration of polynucleic acid sequences of between about 50 $\mu\text{g/ml}$ to about 10 mg/ml of polynucleic acid sequences or molecules. In other preferred embodiments, the aqueous compositions of surfactant and polynucleic acid sequences which form the complexes of the invention comprises a concentration of polynucleic acid sequences of between about 100 $\mu\text{g/ml}$ to about 1 mg/ml of polynucleic acid sequences or molecules.

For example, one embodiment of the complexes of the inventions contains about 0.1-5.0 mg/ml polynucleic acid in a final concentration of 0.010-0.030% w/v benzylammonium-group containing surfactant. Some preferred embodiments comprise 0.010% w/v benzylammonium-containing surfactant and 0.1 mg/ml polynucleic acid molecules. Other preferred embodiments comprise 0.010% w/v benzylammonium-group containing surfactant with about 0.5 mg/ml nucleic acid

molecules. Still other preferred embodiments comprise 0.020% w/v benzylammonium-group containing surfactant with about 0.5 mg/ml nucleic acid molecules.

A particularly desirable embodiment of the complexes of the present invention is formed by between about 100-500 μ g DNA molecules at a concentration of 0.1-0.5 mg/ml in a final concentration of 0.010- 0.030% w/v benzalkonium chloride or benzethonium chloride. Another preferred embodiment comprises 0.010% w/v benzalkonium chloride and 0.1 mg/ml nucleic acid molecules. Still other preferred embodiments comprise 0.010% w/v benzalkonium chloride and about 0.5 mg/ml nucleic acid molecules. Some preferred embodiments comprise 0.020% w/v benzalkonium chloride and 0.5 mg/ml nucleic acid molecules. Some preferred
10 embodiments comprise 0.010% w/v benzethonium chloride and 0.1 mg/ml nucleic acid molecules. Some preferred embodiments comprise 0.010% w/v benzethonium chloride and 0.5 mg/ml nucleic acid molecules. Some preferred embodiments comprise 0.020% w/v benzethonium chloride and 0.5 mg/ml nucleic acid molecules.

The polynucleic acid sequence of this invention may be any nucleic
15 acid sequence and may take a variety of known forms, as taught elsewhere in the art. Thus, as used herein, the terms "polynucleic acid sequence", "nucleic acid molecule", "polynucleotide", "DNA construct", "genetic construct" and "nucleotide sequence" are interchangeable. Polynucleic acid sequences of this invention can be deoxyribonucleic acid sequences (DNA) and/or ribonucleic acid sequences (RNA). These nucleic acid
20 sequences or molecules may be cDNA, genomic DNA, synthesized DNA, DNA molecules or plasmids or a hybrid thereof, or an RNA molecule such as mRNA. The polynucleic acid sequence may also encode antisense sequences which inhibit gene expression of genes whose expression is undesirable. A polynucleic acid molecule may serve as a template for antisense molecules and ribozymes and such sequences may be
25 preferably linked to regulatory elements necessary for production of sufficient copies of the antisense and ribozyme molecules encoded thereby respectively or a ribozyme.

Polynucleic acid sequences or molecules useful in the present invention may serve a variety of functions, but are essentially provided to a selected host cell for a multitude of known therapeutic, prophylactic, and research uses. For example, the

sequences are useful in the complexes of the invention as: 1) sequences encoding for proteins that function as prophylactic and/or therapeutic immunizing agents; 2) replacement copies of defective, missing or non-functioning genes; 3) sequences encoding therapeutic proteins; 4) antisense sequences or sequences encoding for antisense molecules; or 5) sequences encoding for, or genetic templates for, ribozymes.

5 Thus, in desired embodiments, the polynucleic acid sequence or molecule may comprise a sequence that encodes a peptides or protein. The sequence may be a plasmid which comprises a nucleotide sequence that encodes a protein or peptide, the encoding sequence operably linked to regulatory sequences directing
10 expression of the protein or peptide in a host cell. Such regulatory sequences direct replication, transcription, translation and/or expression of the encoded protein or peptide in selected host cells, e.g., mammalian or vertebrate cells. As used herein, the term "expressible form" refers to polynucleic acid sequences or gene constructs which contain the necessary regulatory elements operably linked to a coding sequence that encodes a target protein, such that when present in the host cell, the coding sequence
15 will be expressed.

 The regulatory elements necessary for expression of a sequence encoding a protein or peptide include a promoter (constitutive or inducible), an initiation signal or codon, a termination signal or stop codon, and a polyadenylation signal. In addition, enhancers are often required, as well as other sequences, e.g., a
20 Kozak region, etc. Such regulatory elements may be selected from among those known to be preferred in a selected host cell, and the polynucleic acid sequence may likewise contain codons which are known to be preferentially expressed in certain host cells. Such regulatory elements are operable in the cell of a mammalian or vertebrate subject or tissue to whom they are administered. Initiation codons and stop codon are
25 generally considered to be part of a nucleotide sequence that encodes the desired protein. However, it is necessary that these elements are functional in the individual to whom the gene construct is administered. The initiation and termination codons must be in frame with the coding sequence.

Promoters and polyadenylation signals used must be functional within the host cells. Examples of promoters useful to practice the present invention, especially in the production of a genetic vaccine or gene therapy vector, include but are not limited to, promoters from Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV) promoter, Human Immunodeficiency Virus (HIV) such as the HIV
5 Long Terminal Repeat (LTR) promoter, Moloney virus, ALV, Cytomegalovirus (CMV) such as the CMV immediate early promoter, Epstein Barr Virus (EBV), Rous Sarcoma Virus (RSV) as well as promoters from human genes such as human actin, human myosin, human hemoglobin, human muscle creatine and human metallothionein.

Examples of polyadenylation signals useful to practice the present
10 invention, especially in the production of a genetic vaccine for humans, include but are not limited to SV40 polyadenylation signals and LTR polyadenylation signals. In particular, the SV40 polyadenylation signal which is in pCEP4 plasmid (Invitrogen, San Diego, CA), referred to as the SV40 polyadenylation signal, is used.

In addition to the regulatory elements required for DNA expression,
15 other elements may also be included in the polynucleic acid sequence of the complex. Such additional elements include enhancers, such as those selected from the group including but not limited to: human actin, human myosin, human hemoglobin, human muscle creatine and viral enhancers such as those from CMV, RSV and EBV. The polynucleic acid sequences of this invention may also include a mammalian origin of
20 replication in order to maintain the construct extrachromosomally and produce multiple copies of the construct in a mammalian or vertebrate cell. Plasmids pCEP4 and pREP4 from Invitrogen (San Diego, CA) contain the Epstein Barr virus origin of replication and nuclear antigen EBNA-1 coding region which produces high copy episomal replication without integration.

25 Additionally, polynucleic acid sequence (e.g., DNA) which is useful to promote integration of the polynucleic acid sequence into the chromosome of the cell may also be included in the polynucleic acid sequence or DNA molecule useful in this invention. One embodiment of a polynucleic acid sequence is as a linear minichromosome including a centromere, telomeres and an origin of replication.

The polynucleic acid sequence may also contain an additional element which serves as a target for cell destruction if it is desirable to eliminate cells receiving the sequence for any reason. A herpes thymidine kinase (tk) gene in an expressible form can be included in the polynucleic acid molecule of the complex. Upon administration of the drug gancyclovir, any cell transfected with the complex and thus
5 producing tk, will be selectively killed. Thus, the polynucleic acid sequence can provide the means for the selective destruction of cells transfected therewith.

Depending on the use to which the complex is applied, the polynucleic acid sequence may encode a wide variety of peptides or proteins useful in pharmaceutical reagents and in research. As one example, the proteins and/or peptides
10 encoded by the polynucleic acid sequence of the vesicular complex can include a target protein useful to induce or elicit a therapeutic or prophylactic immune response. The target protein is an immunogenic protein which shares at least an epitope with a protein from the pathogen (e.g., a virus, a bacterium, yeast, parasite, etc) or from an undesirable cell-type such as a cancer cell or a cell involved in autoimmune disease
15 against which immunization is required. The protein can be an epitope identical or substantially similar to an epitope of a antigen of the pathogenic microorganism or undesirable cell type. As used herein, the term "substantially similar epitope" is meant to refer to an epitope that has a structure which is not identical to an epitope of a protein but nonetheless invokes a cellular or humoral immune response which cross
20 reacts to that protein. The protein can be an epitope identical or substantially similar to an epitope of a protein associated with, e.g., hyperproliferating cells; or an epitope identical or substantially similar to an epitope of a protein associated with, e.g, cells that characterize an autoimmune disease.

The polynucleic acid sequence may also encode a therapeutic or
25 compensating protein, i.e., it can encode a protein or peptide which can compensate for a protein product that is deficient, missing, nonfunctional or partially functioning, endogenously produced, in a cell or mammalian or vertebrate subject due to an absent, defective, non-functioning or partially functioning endogenous gene. The polynucleic

acid sequence can also encode a protein or peptide that produces a therapeutic effect in a mammalian or vertebrate subject.

Exemplary protein products can readily be selected by one of skill in the art for insertion into a host cell. Among the non-exclusive lists of protein-encoding polynucleic acid sequences are sequences from an oncogene selected from the group consisting of *myb*, *myc*, *fyn*, *ras*, *sarc*, *neu* and *trk*. The sequences can also encode a protein product of the translocation gene *bcl/abl*; a protein product of P53; or for example, the protein EGRF. Still other exemplary polynucleic acid sequences useful in various aspects of this invention can encode a variable region of an antibody made by a B cell lymphoma; a variable region of a T cell surface receptor of a T cell lymphoma; a variable region of an antibody involved in B cell mediated autoimmune disease; and a variable region of a T cell surface receptor involved in T cell mediated autoimmune disease.

Thus, any polynucleic acid sequence which is desired to be inserted in a selected host cell can form part of the vesicular-like or liposomal-like complex of the present invention. One of skill in the art of therapeutics, vaccines and gene therapy may readily select and incorporate a desired polynucleic acid sequence using the teachings of the present invention.

C. *The Buffer and Other Reagents in the Complex*

The aqueous mixture of the benzylammonium-containing surfactant and the polynucleic acid sequence which form the soluble ionic complexes or vesicular complexes of the invention may also contain other optional agents, such as aqueous buffering agents, isotonicity adjusting agents, and pH adjusting agents. Suitable buffers for use in forming the complexes may be conventionally selected from among many known buffers used in the formation of pharmaceutical products. Among a non-exclusive list of buffers are phosphate buffers, such as phosphate buffered saline and citrate buffers. Selection of such buffers is clearly within the skill of the art. Preferably, the aqueous mixture which forms the complexes contains a buffer in a concentration of about 2 to about 50 mM, preferably about 5 to 30 mM. In one embodiment, the composition contains about 5mM phosphate buffered saline.

The compositions of the present invention may also preferably contain isotonicity adjusting agents. For example, for pharmaceutical compositions for parenteral administration, especially intramuscularly, subcutaneously and intradermally, the aqueous mixture forming the complexes is desirably isotonic. However, as desired, one of skill in the art may readily make the compositions hypotonic or hypertonic.

5 Some examples of typical tonicity adjusting agents include, without limitation, sodium chloride, sucrose, mannitol, sorbitol, and trehalose. For example, where the complex is desirably hypotonic to isotonic, an tonicity adjusting agent, e.g., sucrose, is present in the aqueous admixture forming the complex in a concentration of 0 to about 9.25% w/v. For example, where the complex is desirably hypertonic, an tonicity adjusting
10 agent, e.g., sucrose, is present in the aqueous admixture forming the complex in a concentration of greater than 9% w/v. One of skill in the art of pharmaceutical preparation can readily adjust this characteristic of the complex.

Similarly, ionic strength of the complex may be adjusted by one of skill in the art by the addition of charged molecules, such as sodium chloride. In the
15 examples below, sodium chloride is present at a concentration of between about 0 - 0.9% w/v.

The aqueous mixture forming the complexes of this invention are preferably characterized by a pH between about 6.0 to about 8.0. More preferably, a desirably pH is about 6.7 ± 0.5 . Suitably pH adjustments may be readily made by a
20 selection of agents and is well within the knowledge of one skilled in the pharmaceutical arts.

D. Examples of Complexes of the Invention

According to one embodiment of the invention, a soluble ionic complex is formed by an isotonic, aqueous admixture benzalkonium chloride and plasmid DNA,
25 such as illustrated in Examples 1 and 4 below. In another example of the invention illustrated below, the complex of this invention is formed from an aqueous, isotonic mixture of benzethonium chloride and plasmid DNA, as illustrated in Example 5. Such compositions comprise the polynucleic acid sequence substantially packaged in the vesicular complex formed by an aqueous mixture of a benzylammonium-containing

surfactant and the sequence, as demonstrated by Examples 2 and 3. Similarly, other compositions of this invention contain multiple vesicular complexes of uniform size, each vesicular complex containing polynucleic acid sequence substantially packaged in the complexes formed by admixing an aqueous mixture of the benzylammonium-containing surfactant and a solution containing the polynucleic acid sequence. The method of preparing such complexes of the invention is described in detail in Example 1 below.

The compositions of this invention, i.e., the complexes formed by the benzylammonium-group containing surfactants and polynucleic acid sequences, increase and/or facilitate uptake and/or expression of the polynucleic acid sequences by host cells, compared to the uptake or expression which occurs when the identical polynucleic acid sequence or molecule is administered to a host cell in the absence of the benzylammonium-group containing surfactants. See the results of Example 3 below.

15 **II. *Pharmaceutical Compositions of this Invention***

The complexes and compositions of this invention may be employed in pharmaceutical compositions and in methods to introduce polynucleic acid sequences, e.g., genetic material, into cells *in vitro* or *in vivo*. A pharmaceutical composition of this invention comprises the soluble ionic complexes as described above in a suitable pharmaceutical carrier. In some instances, the aqueous buffer may itself be suitable. The vaccines and therapeutics according to the present invention are formulated according to the mode of administration to be used. One having ordinary skill in the art can readily formulate a pharmaceutical composition that comprises a complex as described above. In cases where intramuscular injection is the chosen mode of administration, an isotonic formulation is preferably used. Generally, additives for tonicity can include sodium chloride, dextrose, mannitol, sorbitol and lactose. In some cases, isotonic solutions such as phosphate buffered saline are preferred. Stabilizers include gelatin and albumin. In some embodiments, a vasoconstriction agent is added to the formulation. The pharmaceutical preparations according to the present

invention are provided sterile and pyrogen free. Although for pharmaceutical use, any route of administration may be employed, it is preferred that the composition of the invention be an injectable formulation. In one embodiment of the invention a pharmaceutical composition comprises a vesicular complex which contains the polynucleic acid molecule substantially packaged in the vesicle, with some minor amount of the sequence associated with the exterior of the vesicular complex, with the complex being in a suitable pharmaceutical carrier.

The compositions of the present invention, when used as pharmaceutical compositions, can comprise about 1 ng to about 1000 μ g of DNA. In some preferred embodiments, the vaccines and therapeutics contain about 10 ng to about 800 μ g DNA. In some preferred embodiments, the vaccines and therapeutics contain about 0.1 to about 500 μ g DNA. In some preferred embodiments, the vaccines and therapeutics contain about 1 to about 350 μ g DNA. In some preferred embodiments, the vaccines and therapeutics contain about 25 to about 250 μ g DNA. In some preferred embodiments, the vaccines and therapeutics contain about 100 μ g DNA.

In addition, other agents which may function as transfecting agents and/or replicating agents and/or inflammatory agents and which may be co-administered with the benzylammonium-group containing surfactants-nucleic acid molecule complexes include growth factors, cytokines and lymphokines such as alpha-interferon, gamma-interferon, platelet derived growth factor (PDGF), colony stimulating factors, such as G-CSF, GM-CSF, tumor necrosis factor (TNF), epidermal growth factor (EGF), and the interleukins, such as IL-1, IL-2, IL-4, IL-6, IL-8, IL-10 and IL-12. Further, fibroblast growth factor, surface active agents such as immune-stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analog including monophosphoryl Lipid A (MPL), muramyl peptides, quinone analogs and vesicular complexes such as squalene and squalene, and hyaluronic acid may also be used administered in conjunction with the compositions of the invention.

The compositions of the present invention may be combined with collagen as an emulsion and delivered parenterally. The collagen emulsion provides a means for sustained release of DNA. Preferably 50 μ l to 2 ml of collagen are used. About 100

µg DNA are combined with 1 ml of collagen in a preferred embodiment using this formulation. Other sustained release formulations such as those described in *Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field. Such formulations include aqueous suspensions, oil solutions and suspensions, emulsions and implants as well as reservoirs and transdermal devices. In some
5 embodiments, time release formulations for compositions of the present invention are provided. In some embodiments, it is preferred that the compositions of the present invention are time released between 6-144 hours, preferably 12-96 hours, more preferably 18-72 hours.

10 **III. Methods of Use of the Complexes**

A. In Vitro Transfection Methods

 The invention provides *in vitro* transfection methods using the complexes and compositions comprising the aqueous mixtures of polynucleic acid sequences and benzylammonium-group containing surfactants as above described.
15 A method of the invention facilitates the uptake of a polynucleic acid sequence into a cell comprising the step of contacting the cell with a soluble ionic complex comprising an aqueous mixture of a benzylammonium group-containing surfactant and a polynucleic acid sequence, as described above. According to this *in vitro* method, the complex may be introduced into tissue cultures or cells in solution in the form of a
20 vesicular complex in which the polynucleic acid sequence is substantially packaged in the complex, with a minor amount of sequence associated with the exterior of the complex.

B. Methods of In Vivo Administration

 The invention also provides *in vivo* therapeutic, prophylactic and gene
25 therapy methods of transferring polynucleic acid sequences (e.g., genetic material) into cells of a mammal or a vertebrate using the pharmaceutical compositions and complexes of this invention. The benzylammonium-group containing surfactants are administered as a mixture with the nucleic acid molecule. In preferred embodiments, the benzylammonium-group containing surfactants are mixed with nucleic acid

molecules to form vesicular complexes. The methods of this invention involve the step of administering to a cell or tissue of the mammal or vertebrate, a composition comprising a benzylammonium-group containing surfactant and a polynucleic acid sequence. Transfection of the polynucleic acid sequence, e.g., the DNA or RNA molecule in the surfactant:polynucleic acid sequence complex, into a living cell results in the expression of the DNA or RNA. Where the DNA or RNA encode a desired protein, the desired protein is produced. When taken up by a cell, the nucleotide sequence encoding the desired protein operably linked to the regulatory elements may remain present in the cell as a functioning extrachromosomal molecule or it may integrate into the cell's chromosomal DNA. The complex may be introduced into cells and the polynucleotide may remain as separate genetic material in the form of a plasmid. Alternatively, the complex can be employed to introduce a linear polynucleic acid sequence (DNA) into the cell, which DNA can integrate into the chromosome. When introducing the complex into the cell, reagents which promote DNA integration into chromosomes may be added.

15 i. Inducing Immune Responses and Therapeutic Treatment

 According to some aspects of the present invention, compositions and methods are provided which prophylactically and/or therapeutically immunize an individual against a pathogen, allergen or abnormal, disease-related cell. In one embodiment, the invention provides a method of inducing an immune response in a mammalian or vertebrate subject, preferably a human, to a pathogenic antigen comprising the step of administering to cells of said subject, an effective amount of a composition or soluble complex as described above. In this complex, the polynucleic acid sequence comprises a sequence which encodes at least one epitope that is identical or substantially similar to an epitope of an antigen of the pathogen against which an immune response can be generated which will be directed against the target pathogen antigen, allergen or antigen of an abnormal and/or disease-related cell. The polynucleic acid sequence can also encode a peptide or protein which is immunologically cross reactive to the target pathogen antigen, allergen or antigen of an abnormal and/or disease-related cell. The epitope-encoding sequence, which is part of the

polynucleotide sequence, is under the control of regulatory sequences that direct expression of said protein in the cells or tissue of the mammalian or vertebrate subject.

In a similar embodiment, the invention provides a method of immunizing a mammalian or vertebrate subject against a disease comprising the step of administering to said subject a composition comprising an effective amount of a composition comprising a complex of this invention, where the polynucleic acid
5 sequence comprises a nucleotide sequence encoding a target protein, operatively linked to regulatory sequences directing the expression of said protein in the cells of said subject. The target protein can be an epitope identical or substantially similar to an epitope of a protein associated with cells that characterize the disease.

10 In other aspect, the method of the invention permits therapeutic treatment of a mammalian or vertebrate subject for a disease comprising the step of administering to cells of said subject, an effective amount of a composition comprising a complex described above. In the complexes useful in this aspect of the invention, the polynucleic acid sequence comprises a sequence which encodes a protein or peptide
15 that produces a therapeutic effect on the subject, said protein-encoding sequence under the control of regulatory sequences that direct expression of said protein in the cells of said subject.

According to these aspects of the present invention, the DNA or RNA that encodes a desired protein is introduced into the cells of an individual where
20 it is expressed, thus producing the desired protein. In such embodiments, an immune response is generated that is immunologically cross reactive with a pathogen antigen, allergen or antigen of the abnormal and/or disease-related cell. The resulting immune response is broad based: in addition to a humoral immune response, immune responses from both arms of the cellular immune response are elicited. The methods of the
25 present invention are useful for conferring prophylactic and therapeutic immunity. Thus, a method of immunizing includes both methods of protecting an individual from pathogen challenge, or occurrence or proliferation of specific cells as well as methods of treating an individual suffering from pathogen infection, hyperproliferative disease or autoimmune disease with which the target protein is associated.

This aspect of the method of the present invention is useful to immunize individuals against pathogenic agents and organisms such that an immune response against a pathogen protein provides protective immunity against the pathogen. The present invention is useful to combat hyperproliferative diseases and disorders such as cancer by eliciting an immune response against a target protein that is specifically associated with the hyperproliferative cells. The present invention is useful to combat autoimmune diseases and disorders by eliciting an immune response against a target protein that is specifically associated with cells involved in the autoimmune condition.

In some preferred embodiments related to immunization applications, the genetic construct contains nucleotide sequences that encode a target protein and further include genes for proteins which enhance the immune response against such target proteins. Examples of such genes are those which encode cytokines and lymphokines such as those listed above in Part II. In some embodiments, it is preferred that the gene for B7.2 and/or GM-CSF is included in genetic constructs used in immunizing compositions.

The present invention may be used to immunize an individual against all pathogens such as viruses, prokaryote and pathogenic eukaryotic organisms such as unicellular pathogenic organisms and multicellular parasites. The present invention is particularly useful to immunize an individual against those pathogens which infect cells and which are not encapsulated, such as viruses, and prokaryote such as gonorrhoeae, listeria and shigella. In addition, the present invention is also useful to immunize an individual against protozoan pathogens which include a stage in the life cycle where they are intracellular pathogens. As used herein, the term "intracellular pathogen" is meant to refer to a virus or pathogenic organism that, for at least part of its reproductive or life cycle, exists within a host cell and therein produces or causes to be produced, pathogen proteins. One of skill in the art, given this disclosure can readily select viral families and genera, or pathogens including prokaryotic and eukaryotic protozoan pathogens as well as multicellular parasites, for which vaccines according to the present invention can be made. See, e.g., the tables of such pathogens

in general immunology texts and in U. S. Patent No. 5,593,972. In some preferred embodiments, the methods of immunizing an individual against a pathogen are directed against HIV, HTLV or HBV.

Because DNA and RNA are both relatively small and can be produced relatively easily, the present invention provides the additional advantage of allowing for vaccination with multiple pathogen antigens. The polynucleic acid sequence used in a composition such as a genetic vaccine employing a complex of this invention can include genetic material which encodes many pathogen antigens. For example, several viral genes may be included in a single construct thereby providing multiple targets. In addition, multiple inoculants which can be delivered to different cells in an individual can be prepared to collectively include, in some cases, a complete or, more preferably, an incomplete such as a near complete set of genes in the vaccine. For example, a complete set of viral genes may be administered using two constructs which each contain a different half of the genome which are administered at different sites. Thus, an immune response may be invoked against each antigen without the risk of an infectious virus being assembled. This allows for the introduction of more than a single antigen target and can eliminate the requirement that protective antigens be identified.

Another aspect of the present invention provides a method of conferring a broad based protective immune response against hyperproliferating cells that are characteristic in hyperproliferative diseases and to a method of treating individuals suffering from hyperproliferative diseases. In such methods, the introduction of complexes of this invention serves as an immunotherapeutic, directing and promoting the immune system of the individual to combat hyperproliferative cells that produce the target protein. As used herein, the term "hyperproliferative diseases" is meant to refer to those diseases and disorders characterized by hyperproliferation of cells. Examples of hyperproliferative diseases include all forms of cancer and psoriasis. It has been discovered that introduction of a genetic construct that includes a nucleotide sequence which encodes an immunogenic "hyperproliferating cell-associated protein" into the cells of an individual results in the production of those proteins in the

vaccinated cells of an individual. As used herein, the term "hyperproliferative associated protein" is meant to refer to proteins that are associated with a hyperproliferative disease. To immunize against hyperproliferative diseases, a complex of the invention that includes a polynucleic acid sequence which encodes a protein that is associated with a hyperproliferative disease is administered to an individual.

5 In order for the hyperproliferative-associated protein to be an effective immunogenic target, it must be a protein that is produced exclusively or at higher levels in hyperproliferative cells as compared to normal cells. Target antigens include such proteins, fragments thereof and peptides which comprise at least an epitope found on such proteins. In some cases, a hyperproliferative-associated protein
10 is the product of a mutation of a gene that encodes a protein. The mutated gene encodes a protein which is nearly identical to the normal protein except it has a slightly different amino acid sequence which results in a different epitope not found on the normal protein. Such target proteins include those which are proteins encoded by oncogenes such as *myb*, *myc*, *fyn*, and the translocation gene *bcr/abl*, *ras*, *src*, P53,
15 *neu*, *trk* and EGRF.

In addition to oncogene products as target antigens, target proteins for anti-cancer treatments and protective regimens include variable regions of antibodies made by B cell lymphomas and variable regions of T cell receptors of T cell lymphomas which, in some embodiments, are also used target antigens for autoimmune
20 disease. Other tumor-associated proteins can be used as target proteins such as proteins which are found at higher levels in tumor cells including the protein recognized by monoclonal antibody 17-1A and folate binding proteins.

While the present invention may be used to immunize an individual against one or more of several forms of cancer, the present invention is
25 particularly useful to prophylactically immunize an individual who is predisposed to develop a particular cancer or who has had cancer and is therefore susceptible to a relapse. Developments in genetics and technology as well as epidemiology allow for the determination of probability and risk assessment for the development of cancer in

individual. Using genetic screening and/or family health histories, it is possible to predict the probability a particular individual has for developing any one of several types of cancer.

Similarly, those individuals who have already developed cancer and who have been treated to remove the cancer or are otherwise in remission are particularly susceptible to relapse and reoccurrence. As part of a treatment regimen, such individuals can be immunized against the cancer that they have been diagnosed as having had in order to combat a recurrence. Thus, once it is known that an individual has had a type of cancer and is at risk of a relapse, they can be immunized in order to prepare their immune system to combat any future appearance of the cancer.

The present invention provides a method of treating individuals suffering from autoimmune diseases and disorders by conferring a broad based protective immune response against targets that are associated with autoimmunity including cell receptors and cells which produce "self"-directed antibodies. T cell mediated autoimmune diseases include Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome, sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis. Each of these diseases is characterized by T cell receptors that bind to endogenous antigens and initiate the inflammatory cascade associated with autoimmune diseases. Vaccination against the variable region of the T cells would elicit an immune response including CTLs to eliminate those T cells.

In RA, several specific variable regions of T cell receptors (TCRs) which are involved in the disease have been characterized. These TCRs include V β -3, V β -14, V β -17 and V α -17. Thus, vaccination with a DNA construct that encodes at least one of these proteins will elicit an immune response that will target T cells involved in RA [Howell, M.D *et al*, Proc. Natl. Acad. Sci. USA, 88:10921-10925 (1991); Paliard, X. *et al*, Science, 253:325-329 (1991); Williams, W.V. *et al*, J. Clin. Invest., 90:326-333 (1992)]. In MS, several specific variable regions of TCRs which are involved in the disease have been characterized. These

TCRs include $V\beta$ -7 and $V\alpha$ -10. Thus, vaccination with a DNA construct that encodes at least one of these proteins will elicit an immune response that will target T cells involved in MS [Wucherpfennig, K.W., *et al.*, Science, 248:1016-1019 (1990); Oksenberg, J.R., *et al.*, Nature, 345:344-346 (1990)]. In scleroderma, several specific variable regions of TCRs which are involved in the disease have been characterized.

- 5 These TCRs include $V\beta$ -6, $V\beta$ -8, $V\beta$ -14 and $V\alpha$ -16, $V\alpha$ -3C, $V\alpha$ -7, $V\alpha$ -14, $V\alpha$ -15, $V\alpha$ -16, $V\alpha$ -28 and $V\alpha$ -12. Thus, vaccination with a DNA construct that encodes at least one of these proteins will elicit an immune response that will target T cells involved in scleroderma.

- 10 In order to treat patients suffering from a T cell mediated autoimmune disease, particularly those for which the variable region of the TCR has yet to be characterized, a synovial biopsy can be performed. Samples of the T cells present can be taken and the variable region of those TCRs identified using standard techniques. Genetic vaccines using the complexes of this invention can be prepared using this information.

- 15 B cell mediated autoimmune diseases include Lupus (SLE), Graves disease, myasthenia gravis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, asthma, cryoglobulinemia, primary biliary sclerosis and pernicious anemia. Each of these diseases is characterized by antibodies which bind to endogenous antigens and initiate the inflammatory cascade associated with
- 20 autoimmune diseases. Vaccination against the variable region of antibodies would elicit an immune response including CTLs to eliminate those B cells that produce the antibody. In order to treat patients suffering from a B cell mediated autoimmune disease, the variable region of the antibodies involved in the autoimmune activity must be identified. A biopsy can be performed and samples of the antibodies present at a site
- 25 of inflammation can be taken. The variable region of those antibodies can be identified using standard techniques. Genetic vaccines can be prepared using this information. For example, in the case of SLE, one antigen is believed to be DNA. Thus, in patients to be immunized against SLE, their sera can be screened for anti-DNA antibodies and a vaccine can be prepared which includes DNA constructs that encode the variable

region of such anti-DNA antibodies found in the sera.

Common structural features among the variable regions of both TCRs and antibodies are well known. The DNA sequence encoding a particular TCR or antibody can generally be found following well known methods such as those described in Kabat, et al. (1987) *Sequence of Proteins of immunological Interest* U.S. Department of Health and Human Services, Bethesda MD. In addition, a general method for cloning functional variable regions from antibodies can be found in Chaudhary, V.K., et al., Proc. Natl. Acad. Sci. USA 87:1066 (1990).

In some embodiments of the invention, the individual is subject to a single vaccination to produce a full, broad immune response. In some
10 embodiments of the invention, the individual is subject to a series of vaccinations to produce a full, broad immune response. According to some embodiments of the invention, at least two and preferably four to five injections are given over a period of time. The period of time between injections may include from 24 hours apart to two weeks or longer between injections, preferably one week apart. Alternatively, at least
15 two and up to four separate injections are given simultaneously at different sites.

In some embodiments of the invention, a complete vaccination includes injection of a single inoculant which contains a compositions of this invention which includes a polynucleic acid sequence including sequences encoding one or more targeted epitopes.

20 In some embodiments of the invention, a complete vaccination includes injection of two or more different inoculants into different sites. For example, in an HIV vaccine according to the invention, the vaccine comprises two inoculants in which each one comprises compositions of this invention encoding different viral proteins. This method of vaccination allows the introduction of as much as a complete
25 set of viral genes into the individual without the risk of assembling an infectious viral particle. Thus, an immune response against most or all of the virus can be invoked in the vaccinated individual. Injection of each inoculant is performed at different sites, preferably at a distance to ensure no cells receive both genetic constructs. As a further safety precaution, some genes may be deleted or altered to further prevent the

capability of infectious viral assembly.

ii. Gene Therapy

Other aspects of the present invention relate to gene therapy; that is, to compositions for and methods of introducing nucleic acid molecules into the cells of an individual exogenous copies of genes which either correspond to defective, missing, non-functioning or partially functioning genes in the individual or which
5 encode therapeutic proteins, i.e., proteins whose presence in the individual will eliminate a deficiency in the individual and/or whose presence will provide a therapeutic effect on the individual thereby providing a means of delivering the protein by an alternative means from protein administration. In aspects of the invention
10 relating to gene therapy, constructs with origins of replication including the necessary antigen for activation are preferred. Thus, a method of treating a mammalian or vertebrate subject for a disease comprises administering to cells of said subject, an effective amount of a composition comprising a complex as above-described. The polynucleic acid sequence of the complex which is useful in this method comprises a
15 sequence which encodes a protein that compensates for a missing, non-functional or partially functioning native mammalian protein, said protein-encoding sequence under the control of regulatory sequences that direct expression of said protein in the cells of said subject.

In some of the embodiments of the invention that relate to gene
20 therapy, the gene constructs contain either compensating genes or genes that encode therapeutic proteins. Examples of compensating genes include a gene which encodes dystrophin or a functional fragment, a gene to compensate for the defective gene in patients suffering from cystic fibrosis, an insulin, a gene to compensate for the defective gene in patients suffering from ADA, and a gene encoding Factor VIII.
25 Examples of genes encoding therapeutic proteins include genes which encodes erythropoietin, interferon, LDL receptor, GM-CSF, IL-2, IL-4 and TNF. Additionally, genetic constructs which encode single chain antibody components which specifically bind to toxic substances can be administered.

In some preferred embodiments, the dystrophin gene is provided as part of a mini-gene and used to treat individuals suffering from muscular dystrophy. In some preferred embodiments, a mini-gene which contains coding sequence for a partial dystrophin protein is provided. Dystrophin abnormalities are responsible for both the milder Becker's Muscular Dystrophy (BMD) and the severe Duchenne's Muscular Dystrophy (DMD). In BMD dystrophin is made, but it is abnormal in either size and/or amount. The patient is mild to moderately weak. In DMD no protein is made and the patient is wheelchair-bound by age 13 and usually dies by age 20. In some patients, particularly those suffering from BMD, partial dystrophin protein produced by expression of a mini-gene delivered according to the present invention can provide improved muscle function.

In some preferred embodiments, genes encoding IL-2, IL-4, interferon or TNF are delivered to tumor cells which are either present or removed and then reintroduced into an individual. In some embodiments, a gene encoding gamma interferon is administered to an individual suffering from multiple sclerosis.

Antisense molecules and ribozymes may also be delivered to the cells of an individual by introducing genetic material which acts as a template for copies of such active agents. These agents inactivate or otherwise interfere with the expression of genes that encode proteins whose presence is undesirable. Constructs which contain sequences that encode antisense molecules can be used to inhibit or prevent production of proteins within cells. Thus, production proteins such as oncogene products can be eliminated or reduced. Similarly, ribozymes can disrupt gene expression by selectively destroying messenger RNA before it is translated into protein. In some embodiments, cells are treated according to the invention using constructs that encode antisense or ribozymes as part of a therapeutic regimen which involves administration of other therapeutics and procedures. Gene constructs encoding antisense molecules and ribozymes use similar vectors as those which are used when protein production is desired except that the coding sequence does not contain a start codon to initiate translation of RNA into protein. In some

embodiments, it is preferred that the vectors contain an origin of replication and an expressible form of the appropriate nuclear antigen.

Ribozymes are catalytic RNAs which are capable of self-cleavage or cleavage of another RNA molecule. Several different types of ribozymes, such as hammerhead, hairpin, Tetrahymena group I intron, ahead, and RNase P are known in the art [S. Edgington, Biotechnology, 10:256-262 (1992)]. Hammerhead ribozymes have a catalytic site which has been mapped to a core of less than 40 nucleotides. Several ribozymes in plant viroids and satellite RNAs share a common secondary structure and certain conserved nucleotides. Although these ribozymes naturally serve as their own substrate, the enzyme domain can be targeted to another RNA substrate through base-pairing with sequences flanking the conserved cleavage site. This ability to custom design ribozymes has allowed them to be used for sequence-specific RNA cleavage [G. Paolella *et al.*, EMBO J., 1913-1919 (1992)]. It will therefore be within the scope of one skilled in the art to use different catalytic sequences from various types of ribozymes, such as the hammerhead catalytic sequence and design them in the manner disclosed herein. Ribozymes can be designed against a variety of targets including pathogen nucleotide sequences and oncogenic sequences. Certain preferred embodiments of the invention include sufficient complementarity to specifically target the abl-bcr fusion transcript while maintaining efficiency of the cleavage reaction.

20 iii. Routes of Administration

In any of the above described pharmaceutical methods, the complex may be administered by any suitable route for such therapy. Among such routes are included parenteral routes, such as intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, intraocular, and intrathecal routes of administration. Mucosal routes of administration are also useful, including rectal, vaginal, urethral and intranasal routes. Topical and transdermal administration is also useful for compositions and methods of this invention. Administration by inhalation is also useful. Suppository preparations or other appropriate dosage forms are also useful. Oral administration may also be employed in the methods of this

invention. Preferred routes of administration include intramuscular, intraperitoneal, intradermal and subcutaneous injection.

Compositions of this invention may be administered by means including, but not limited to, traditional syringes, needleless injection devices, or "microprojectile bombardment gene guns". According to some embodiments of the present invention, the complex of this invention is simultaneously administered to an individual intradermally, subcutaneously and intramuscularly using a needleless injection device. Needleless injection devices are well known and widely available. One having ordinary skill in the art can, following the teachings herein, use needleless injection devices to deliver compositions of this invention to cells of an individual.

Needleless injection devices are well suited to deliver compositions of this invention to all tissue. They are particularly useful to deliver compositions of this invention to skin and muscle cells, intradermally, subcutaneously and intramuscularly. In some embodiments, a needleless injection device may be used to propel a liquid that contains the surfactant:DNA complexes toward the surface of the individual's skin. The liquid is propelled at a sufficient velocity such that upon impact with the skin the liquid penetrates the surface of the skin, permeates the skin and muscle tissue therebeneath. In some embodiments, a needleless injection device may be used to deliver compositions of this invention to tissue of other organs in order to introduce a nucleic acid molecule to cells of that organ.

According to methods of this invention, complexes or compositions of this invention may be administered directly into the individual to be immunized. By any route, the compositions of this invention are introduced into cells which are present in the body of the individual. Delivery of the polynucleic acid sequences which encode target proteins can confer mucosal immunity in individuals immunized by a mode of administration in which the material is presented in tissues associated with mucosal immunity. Thus, in some examples, the complex of this invention is delivered by administration in the buccal cavity within the mouth of an individual, or administered rectally, vaginally, or to the urethra.

Alternatively, the compositions may be introduced by various means *ex vivo* into removed cells of the individual which are reimplanted after administration. Such means include, for example, *ex vivo* transfection, electroporation, microinjection and microprojectile bombardment. After the complex of the invention is taken up by the cells, the cells are reimplanted into the individual. It is contemplated
5 that otherwise non-immunogenic cells that have the polynucleic acid sequences incorporated therein can be implanted into the individual even if the vaccinated cells were originally taken from another individual.

In some embodiments, the compositions of the present invention comprise as the polynucleic acid sequence an attenuated viral vaccine that may be
10 delivered as a genetic construct. Such constructs may allow for production of viral particles. Delivery of the attenuated vaccine as a polynucleic acid sequence in a complex of this invention allows for an easier way to produce large quantities of safe, pure active immunizing product.

In some embodiments, the compositions of the present invention
15 may be administered with or without the use microprojectiles. In some embodiments, the compositions of the present invention may be delivered to the cells of an individual free of solid particles. As used herein, the phrase "free of solid particles" is meant to refer to a liquid that does not contain any solid microprojectile used as a means to perforate, puncture or otherwise pierce the cell membrane of a cell in order to create a
20 port of entry for compositions of this invention into the cell. For example, the compositions of the present invention are administered by means of a microprojectile particle bombardment procedure as taught by Sanford et al. in U.S Patent 4,945,050 issued July 31, 1990. In some embodiments of the invention, the compositions of the present invention are administered as part of a liposome complex.

25 The methods of the present invention are useful in the fields of both human and veterinary medicine. Accordingly, the present invention relates to genetic immunization of mammals, and vertebrates, such as birds and fish. The methods of the present invention can be particularly useful for mammalian species including human, bovine, ovine, porcine, equine, canine and feline species.

The following examples illustrate the preferred methods for preparing the benzylammonium-containing surfactant/polynucleic acid complexes of the present invention and further illustrate that such compositions facilitate the uptake of the polynucleic acid. These examples which employ as the surfactant, benzalkonium chloride or benzethonium chloride, and as the polynucleic acid sequences, plasmid sequences containing a herpes simplex virus gD gene merely illustrate selections of the surfactant, the polynucleic acid sequence, the type of sequence and source of the sequence. It is understood by one of skill in the art, that other selections for these components of the invention may be readily selected as taught by this specification. These examples are illustrative only and do not limit the scope of the invention.

10

EXAMPLE 1: A Benzylammonium-Containing Surfactant/Polynucleic Acid Formulation of The Invention

A composition containing uniform ionic, vesicular complexes with polynucleic acid packaged in an aqueous benzylammonium-containing surfactant is formulated according to this invention as follows. For this example, the polynucleic acid sequence component is plasmid DNA, and the benzylammonium-containing surfactant, benzylammonium chloride. The buffer used is phosphate buffer. Other conventional buffers, such as citrate buffer, also can be used instead of phosphate buffer. Tonicity of the resulting solution may be adjusted with sodium chloride, sucrose, other conventionally known isotonic agents, such as mannitol, sorbitol, trehalose, or any non-ionic agents from the list in *Remington's Pharmaceutical Sciences*, supra.

20

An illustrative formulation of this invention is prepared by admixing under conditions of ambient temperature the components listed in Table I. Generally, a stock solution of the benzylammonium-containing compound is prepared in the selected buffer buffer. A polynucleic acid solution, e.g., a DNA or RNA solution is prepared containing the selected concentration of polynucleic acid sequence, e.g., plasmid DNA, in the selected buffer with the tonicity adjusting agent. Before admixture, both solutions are preferably filtered conventionally, for example, using a

25

0.22 µm Millex GV syringe filter. Suitable amount of the surfactant solution is added to suitable volumes of the polynucleic acid by slow mixing. The desired concentration is made by selecting the concentration of surfactant solution and a desired concentration of the polynucleic acid solution.

A composition according to this invention must be soluble. The endpoint of concentrations of the components of the complex is generally precipitation. It is preferred that the charge ratio of the benzylammonium-containing surfactant and the polynucleic acid be less than 1, and that excess positive charge be avoided. The conditions of the solution, and the amounts of polynucleic acid sequence and surfactant can be manipulated to increase solubility and reduce the toxicity of the surfactant concentrations. Desirably, the pH of the admixture is between 6 and 8, and more preferably between 6.2 and 7.2. The desired isotonicity, hypotonicity (<0.9% w/v NaCl or equivalent) or hypertonicity (>0.9% w/v NaCl or equivalent), can be adjusted by tonicity adjusting agents [see, e.g., *Remington's*, cited above].

Table I provides an illustrative composition of the invention. Other ranges of the components of the soluble ionic complex of the invention are disclosed above.

Table I

| Component | Range |
|--|----------------------|
| Plasmid DNA | 10µg/ml - 20.0 mg/ml |
| Benzylammonium containing surfactant | 0.001 - 2.4% w/v |
| Buffer (e.g. phosphate) | 2 - 30 mM |
| Sodium chloride | 0 - 0.9% w/v |
| Tonicity adjusting agent (e.g., sucrose) | 0 - 13% w/v |

EXAMPLE 2: Scanning and Transmission Electron Microscopic Studies with Benzalkonium Chloride:DNA Complexes

Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were employed to visualize the resulting complexes formed by the benzylammonium-containing surfactant and polynucleic acid compositions of this invention.

A. Preliminary Studies

Electron microscope studies were made of the following benzalkonium chloride/DNA complex formulations of the invention:

- a) 0.025% benzalkonium chloride/0.5 mg/mL of DNA,
- b) 0.0125% benzalkonium chloride/0.5 mg/mL DNA,
- c) 0.025% benzalkonium chloride/0.1 mg/mL of DNA,
- d) 0.012 % benzalkonium chloride/0.05 mg/mL of DNA. These formulations were made in the same manner as described for Example 1, except that the benzalkonium chloride concentrations are different as stated above. Each formulation containing 8.71% sucrose w/v and 5 mM phosphate buffer at pH6.7 \pm 0.5.

Electron microscopic photographs (not pictured) illustrated that each formulation formed uniform vesicular complexes indistinguishable from those derived from classical liposomes and cationic liposomes.

B. Additional SEM and TEM Studies

- i. Formulations of this invention were prepared by mixing DNA at 0.5 mg/mL, with benzalkonium chloride (0.02% w/v) in 10 mM citrate or phosphate buffers, pH 6.7 (\pm 0.5), and 50 mM NaCl, substantially as described above.

The structures visible by both SEM and TEM are indistinguishable from those derived from classical liposomes and cationic liposomes. The size of these particles varied from 50 nm to 230 nm. However, most structures had an uniform size distribution ranging from 70 to 100 nm.

- ii. Additional studies were performed by mixing DNA at 5 mg/ml in higher concentrations of benzalkonium chloride, up to 0.04% w/v, in 10 mM citrate or phosphate buffers, pH 6.7 (\pm 0.5), and 50 mM NaCl, substantially as described

above. Benzalkonium chloride alone does not form vesicular complexes in water. At higher than $\geq 0.1\%$ w/v, benzalkonium chloride alone is soluble and forms micelles. However, upon addition of DNA, vesicular complexes are formed, when observed by SEM. The vesicular complexes range in size from 50 (at 0.01% benzalkonium chloride) to 400 nm particles (0.04% w/v benzalkonium chloride). Benzalkonium chloride at concentrations higher than $\geq 0.04\%$ w/v under these conditions, in the presence of DNA formed a fine precipitate that contained DNA (determined by agarose gel electrophoresis of the precipitate). At concentrations above 0.04% benzalkonium chloride under these conditions, the precipitates were snowy and flocculent.

These observations and the SEM and TEM pictures described herein (not pictured) show that benzalkonium chloride:DNA compositions according to this invention form a vesicular-like or liposomal-like structure. The quaternary ammonium cationic head group of the benzalkonium chloride is positively charged independent of protonation, and forms complexes with DNA, that decrease its solubility. At benzalkonium chloride concentrations lower than 0.04% w/v in the compositions above, the complexes remain soluble, while at benzalkonium chloride concentrations $\geq 0.04\%$ w/v in the compositions above, the hydrophilicity of these complexes is reduced to near neutrality. The association of DNA with the precipitates further indicates complexation.

iii. SEM was carried out on formulations that contained two different concentrations of DNA ($100 \mu\text{g/ml}$ and 0.5 mg/ml), and fixed concentrations of benzalkonium chloride (0.02% w/v). Similar particle distribution was found at both concentrations of DNA, but in larger numbers with higher DNA concentrations. Larger particles in higher DNA concentrations appear to have derived from the fusion of several 50 nm particles. Formation of larger particles was dependent on the concentration of DNA in the formulation. These particles were visualized by shadow casting in SEM analysis using carbon, and were visible by short (10 second) exposure to the contrasting agent uranyl acetate in TEM analysis. The TEMs show membranous structures typical of liposomes described in literature.

As controls, SEM of DNA alone and benzalkonium chloride alone in aqueous solutions were performed. Vesicular structures are found only when aqueous solutions of DNA and benzalkonium chloride are mixed. TEMs show structures that are vesicular and some are multilamellar. Membranous structures found in these TEMs are consistent with the formation of lamellar vesicular complexes in liposomes. These results show that benzalkonium chloride:DNA complexes form lamellar and vesicular structures, similar to those described for liposomes and liposomal formulations.

10 EXAMPLE 3: Labeled DNA is Associated with the Vesicular complexes, SEM and TEM Analysis

A. *Preparation of Open Circular Plasmid DNA.*

Supercoiled (SC) plasmid DNA was converted into an open-circular form by heating at 80°C, for 4 hours. Nearly 80% of SC DNA was converted to nicked open circular (OC) form by this method. The amount of DNA converted to OC was quantified using a video gel-scanner, following electrophoretic separation of SC and OC forms. The OC was purified to nearly 95% purity on a Q-Sepharose matrix using a NaCl step gradient.

B. *Preparation of Biotinylated dUTP DNA.*

Fifty micrograms of nicked OC DNA was subjected to a strand displacement reaction using Klenow (the non-proofreading proteolytic fragment of DNA polymerase of *E. coli*), and dNTP. The dNTP mixture contained dATP, dGTP, dCTP, dUTP, and Bio-dUTP. Bio-dUTP has biotin on an 11 carbon linker attached to the base uracil. The nucleotide concentration was at 50 μ M, while the bio-dUTP was at 2 μ M, and dUTP was at 20 μ M. The plasmid was purified from free nucleotides by two rounds of ethanol precipitation, and two 70% ethanol washes. The amount of biotin incorporated into the plasmid was determined by a kinetic ELISA, by reacting dilutions of the plasmid with streptavidin-horseradish peroxidase (HRP). Three molecules of biotin were incorporated per plasmid molecule.

C. *Preparation of Streptavidin-Colloidal Gold Conjugated Plasmid DNA.*

One microgram of a 5 Kbp plasmid DNA corresponds to 1.25×10^{14} molecules (3.75×10^{13} biotin). Five hundred micrograms of mixture in one milliliter was reacted with 10^{11} molecules of gold-conjugated streptavidin. This ensures absence of free streptavidin-gold conjugates [T. Daemen et al, *Hepatology*, 26:416 (1997)].

- 5 Benzalkonium chloride at 0.02% was added to the mixture to form complexes. The mixture was analyzed by TEM.

D. *TEM Analysis*

- TEM analysis of the above-prepared gold labeled DNA in the benzylammonium-containing surfactant/polynucleic acid sequence compositions of this invention demonstrated that the gold-labeled DNA is found in structures (complexes) that are identical to those found by carbon shadowing. These structures show that DNA is within the vesicular membranes. Vesicular complexes in some fields appear to be multilamellar, and the gold labeled plasmid molecules are interspersed within these lamellae. Electron diffraction shows densities corresponding to gold that were
- 10 detected on these membranes, and within membranes. This analysis demonstrates that benzalkonium chloride:DNA complexes form vesicular complexes, and the DNA is in the vesicular space, intimately associated with the membrane.
- 15

EXAMPLE 4: Enhancement of DNA Uptake Using Compositions of the Invention

20 A. *The Formulations Tested*

Four different formulations were prepared to evaluate the ability of aqueous mixtures of benzylammonium-containing surfactants and polynucleic acid sequences to facilitate DNA delivery. The four formulations of the invention and the control are reported in Table 2 below.

- 25 Formulation 1 (2 mL formulation) was prepared as follows: 0.5% benzalkonium chloride stock was prepared in 5 mM phosphate buffer. A DNA plasmid was constructed which contained the Herpes Simplex Virus gene encoding the gD₂ protein linked to a cytomegalovirus promoter and SV40 polyadenylation site. This plasmid, referred to as plasmid 24, is described in detail in International Patent

Publication No. WO97/41892, published November 13, 1997. The DNA plasmid solution was prepared containing 0.5 mg/mL plasmid DNA in 5 mM phosphate buffer with 8.71% sucrose. Both the benzalkonium chloride stock solution and DNA solution were filtered using 0.22 μ m Millex GV syringe filter. Forty μ L of benzalkonium chloride stock solution was added to 1.96 mL of DNA solution (0.5 mg/mL) by slow mixing.

Formulation 2 (2 mL formulation) was prepared as follows: 0.5% benzalkonium chloride stock was prepared in 5 mM phosphate buffer. DNA solution contain the above-described plasmid 24 (0.5 mg/mL) was prepared in 5 mM phosphate buffer with 8.71% sucrose. Both the benzalkonium chloride stock solution and DNA solution were filtered using 0.22 μ m Millex GV syringe filter. Eighty μ L of benzalkonium chloride stock solution was added to 1.92 mL of DNA solution (0.5 mg/mL) by slow mixing.

Formulation 3 (2mL formulation) was prepared as follows: 0.5% benzalkonium chloride stock was prepared in 5 mM phosphate buffer. DNA solution containing the above-described plasmid 24 (0.5mg/mL) was prepared in buffer solution containing 5 mM phosphate and 150 mM of sodium chloride. Both the benzalkonium chloride stock solution and DNA solution were filtered using 0.22 μ m Millex GV syringe filter. One hundred twenty μ L of benzalkonium chloride stock solution was added to 1.88 mL of DNA solution (0.5 mg/mL) by slow mixing.

As a positive control, a DNA only formulation was prepared containing 0.5 mg/mL DNA of plasmid 24 in 30 mM citrate buffer, 0.1% ethylenediamine tetraacetic acid (EDTA), 150 mM NaCl at pH 6.7 \pm 0.5. As a negative control, a DNA only formulation was prepared containing 0.5 mg/ml DNA of plasmid 23 (no HSV insert) in 30 mM citrate buffer, 0.1% EDTA, 150 mM NaCl at pH 6.7 \pm 0.5.

Table 2

| Components | Formulations | | |
|-----------------------------|--------------|---------|---------|
| | 1 | 2 | 3 |
| Plasmid DNA (mg/mL) | 0.5 | 0.5 | 0.5 |
| Benzalkonium chloride (w/v) | 0.01% | 0.02% | 0.06% |
| Sucrose (w/v) | 8.71% | 8.71% | 0 |
| Sodium Chloride (mM) | 0 | 0 | 150 |
| Phosphate buffer (mM) | 5 | 5 | 5 |
| pH | 6.7±0.5 | 6.7±0.5 | 6.7±0.5 |

B. Protocol of Test

Six groups of BALB/c mice (5 mice/group) were immunized intramuscularly with 50 µg plasmid DNA in a total volume of 100 µL per dose, which was distributed between 3-4 sites per leg on Day 1. The plasmid was administered in compositions with different concentrations of benzalkonium chloride as follows:

Group I received Formulation 1 (50 µg plasmid in 0.01% benzalkonium chloride). Group II received Formulation 2 (50 µg plasmid in 0.02% benzalkonium chloride). Group III received Formulation 3 (50 µg plasmid in 0.06% benzalkonium chloride). Group IV received positive control (50 µg plasmid 24 without any transfection facilitating agent); and Group V received negative control (plasmid 23 with no HSV insert and without any transfection facilitating agent).

Serum was collected prior to first injection (Day 0) and at two weeks post injection (Day 14). Animals were boosted once more at the same dosage at four weeks (Day 28). After the final injection an additional serum sample was taken. Two weeks following the final immunization (Day 42), mice were euthanized using halothane, followed by cervical dislocation and the spleens were harvested.

C. *In Vivo Results*

The sera and spleens from each mouse and each group of mice was assayed for humoral response, i.e., antibody response to gD, as measured by a standard enzyme linked immunosorbent assay (ELISA) [J. E. Coligan et al, eds., "Current Protocols in Immunology", Vol. 1, chap. 2.1, John Wiley & Sons, Inc. (1992)]. Figs. 1 and 2 illustrate the humoral responses of individual animals and the group average humoral responses, respectively. Antibody response calculations were conducted as follows. Based on linear regression, a linear model [O.D. = (slope x antibody concentration) + Intercept] was fitted to the standard data. The equation for the best fit line was used to calculate antibody response for specific formulations. Fig. 3 illustrates the individual and group cellular responses of the same animals. Systemic cellular response (SI) was measured using a splenic cell proliferation assay in which was calculated the ratio of the number of spleen cells stimulated in the presence of HSV gD antigen and radiolabelled nucleotides divided by the number of the same spleen cells incubated in the absence of any antigen, but in the presence of radiolabelled nucleotides [J. E. Coligan et al, eds., "Current Protocols in Immunology", Vol. 1, chap. 2.1, John Wiley & Sons, Inc. (1992)].

Fig. 1 demonstrates that Formulation 1 (0.01% benzalkonium chloride and 0.5 mg/mL DNA) produced a significantly higher individual and group humoral response than did the positive control DNA. The group average humoral response (antibody) for Formulation 1 is 2.9 ng/mL higher than the positive control DNA alone formulation. Fig. 1 demonstrates that all five animals in Groups I and II gave humoral responses to Formulations 1 and 2, respectively; whereas only four animals in Group IV, which received the positive control DNA, produced humoral responses. The negative control DNA gave no response, as predictable. Thus, greater consistency and predictability of immune responses was seen with formulations of this invention than with DNA delivered in the absence of a transfection facilitating agent of this invention. Formulation 3 in the preparation used in this experiment produced an undesirable precipitate.

Fig. 3 demonstrates that the cellular responses for Formulations 1 and 2 (Groups I and II, respectively) are comparable to those elicited by administration of positive control DNA only (Group IV). However, again, variation in the cellular responses to formulations of this invention is minimal, compared to the wide variation in responses observed for those animals in Group IV that received DNA alone.

Based on the humoral and cellular responses in animals, as described above, it appears that benzalkonium chloride/DNA complex formulations (Formulations 1 and 2) provide better immune responses compared to DNA alone and facilitates the transfer of DNA into the subject.

EXAMPLE 5: Benzethonium Chloride:DNA Complexes

Compositions according to the present invention were also prepared using another exemplary benzylammonium-containing surfactant as described here, i.e., benzethonium chloride. These formulations were prepared in substantially the same manner as described for the benzalkonium chloride formulations of Example 4 above.

The different formulations appear in Table 3 below.

Table 3


| Components | Formulation 1 | Formulation 2 | Formulation 3 |
|-----------------------------|---------------|---------------|---------------|
| Plasmid DNA (mg/mL) | 0.1 | 0.5 | 0.5 |
| Benzethonium chloride (w/v) | 0.01% | 0.01% | 0.02% |
| Sucrose (w/v) | 8.71% | 8.71% | 8.71% |
| Phosphate buffer (mM) | 5 | 5 | 5 |
| pH | 6.7±0.5 | 6.7±0.5 | 6.7±0.5 |

TEM and SEM analyses of these compositions were performed as described in Example 3. Based on TEM and SEM analysis, the structures have the same description as found for the benzalkonium chloride:DNA vesicular complexes of Example 3, i.e. uniformly sized vesicular complexes which packaged DNA.

All above-noted published references, and the provisional United States patent application No. 60/063,360, are incorporated herein by reference. Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes of the present
5 invention are believed to be encompassed in the scope of the claims appended hereto.

What is claimed is:

1. A soluble ionic complex comprising an aqueous mixture of
 - (a) a benzylammonium group-containing surfactant; and
 - (b) a polynucleic acid sequence.
2. The complex according to claim 1, which forms a vesicular complex containing said polynucleic acid sequence substantially packaged therein.
3. The complex according to claim 1, wherein said benzylammonium group-containing surfactant is a surfactant of the formula:



wherein X is an anion;

each R¹ is independently selected from the group consisting of a hydrogen and a lower alkyl group comprising from 1 to 6 carbon atoms;

R² is selected from the group consisting of CH₂ and -O-;

R³ is selected from the group consisting of H, CH₃, C₂H₅, phenyl, mono-substituted phenyl, and di-substituted phenyl, wherein said substitutions are independently selected from the group consisting of C₁-C₁₀ branched or straight chain alkyls groups; and

n is an integer of 2 through 7, provided that when n is 1, R³ is methyl, ethyl, phenyl or substituted phenyl; when n is 4 through 6, R³ is H, methyl, ethyl or phenyl; when n is 6, R³ is H, methyl or ethyl; and when n is 7, R³ is H or methyl.

4. The complex according to claim 3, wherein X is selected from the group consisting of halide, sulfate, and carbonate.

5. The complex according to claim 4, wherein said benzylammonium group-containing surfactant is a benzalkonium halide.
6. The complex according to claim 5 wherein said halide is chloride and said surfactant is benzalkonium chloride.
7. The complex according to claim 3, wherein said surfactant is a benzethonium halide.
8. The complex according to claim 7, wherein said surfactant is benzethonium chloride.
9. The complex according to claim 1, wherein said benzylammonium containing surfactant is present in a concentration of about 0.001 to about 2.4% w/v.
10. The complex according to claim 9, wherein said benzylammonium containing surfactant is present in a concentration of about 0.001 to about 0.1% w/v.
11. The complex according to claim 10, wherein said benzylammonium containing surfactant is present in a concentration of about 0.005 to about 0.06% w/v.
12. The complex according to claim 11, wherein said benzylammonium containing surfactant is present in a concentration of about 0.005 to about 0.03% w/v.
13. The complex according to claim 1, wherein said polynucleic acid sequence comprises a ribonucleic acid sequence.
14. The complex according to claim 1, wherein said polynucleic acid sequence comprises a deoxyribonucleic acid sequence.

15. The complex according to claim 14, wherein said deoxyribonucleic acid sequence is a plasmid.

16. The complex according to claim 15, wherein said plasmid comprises a nucleotide sequence that encodes a protein or peptide, said sequence operably linked to regulatory sequences directing expression of said protein or peptide in a host cell.

17. The complex according to claim 14, wherein said sequence encodes a protein or a peptide.

18. The complex according to claim 1 wherein said polynucleic acid sequence is present in said complex in a concentration of between about 10 μ g/ml to about 20 mg/ml.

19. The complex according to claim 18 wherein said polynucleic acid sequence is present in said complex in a concentration of between about 50 μ g/ml to about 10 mg/ml.

20. The complex according to claim 19 wherein said polynucleic acid sequence is present in said complex in a concentration of between about 100 μ g/ml to about 1.0 mg/ml.

21. The complex according to claim 1 which further comprises additives selected from the group consisting of buffering agents and tonicity adjusting agents.

22. The complex according to claim 1, wherein said surfactant is benzalkonium chloride, said polynucleic acid is plasmid DNA, and said aqueous mixture is an isotonic solution.

23. A composition comprising a polynucleic acid sequence substantially packaged in a vesicular complex formed by an aqueous mixture of a benzylammonium-containing surfactant and said sequence.

24. A composition comprising multiple vesicular complexes of uniform size, each said vesicular complex containing a polynucleic acid sequence substantially packaged in a vesicular complex formed by an aqueous mixture of a benzylammonium-containing surfactant and said sequence.

25. The composition according to claim 24 formed by mixing an aqueous solution of a benzylammonium-containing surfactant with a polynucleic acid sequence.

26. A pharmaceutical composition comprising the soluble ionic complex of any of claims 1 through 22 in a suitable pharmaceutical carrier.

27. The composition according to claim 26, which is an injectable formulation.

28. A pharmaceutical composition comprising the vesicular complex composition of claims 23 or a composition of any of claims 24 through 25 in a suitable pharmaceutical carrier.

29. A method of introducing a polynucleic acid sequence into a cell comprising the step of contacting said cell with a member of the group consisting of:

- (a) a complex of any of claims 1 through 22;
- (b) a composition of claim 23; and
- (c) a composition of any of claims 24-25; and
- (d) a composition of any of claims 26-29.

30. A method of facilitating the uptake of a polynucleic acid sequence into a cell comprising contacting said cell with a soluble ionic complex comprising an aqueous mixture of

- (a) a benzylammonium group-containing surfactant; and
- (b) a polynucleic acid sequence.

31. The method according to claim 30, wherein said complex is in the form of a vesicular complex in which the polynucleic acid sequence is substantially packaged.

32. A method of inducing an immune response in a mammalian subject to a pathogenic antigen comprising the step of administering to cells of said subject, an effective amount of a composition comprising the complex of claim 1 or 2, wherein said polynucleic acid sequence comprises a sequence which encodes at least one epitope that is identical or substantially similar to an epitope of a antigen of said pathogen, said epitope-encoding sequence under the control of regulatory sequences that direct expression of said protein in the cells of said subject.

33. The method according to claim 32 wherein composition is administered by a route selected from the group consisting of intramuscularly, intraperitoneally, intradermally, subcutaneously, intravenously, intraarterially, intraocularly, orally, topically, transdermally, intrathecally, intranasally, rectally, vaginally, interurethally, buccally and by inhalation.

34. A method of immunizing a mammalian subject against a disease comprising the step of administering to said subject a composition comprising an effective amount of a composition comprising a complex of claim 1 or 2, wherein said polynucleic acid sequence comprises a nucleotide sequence encoding a target protein, said protein comprising an epitope identical or substantially similar to an epitope of a protein associated with cells that characterize said disease, said protein encoding sequence operatively linked to regulatory sequences directing the expression of said protein in the cells of said subject.

35. The method according to claim 36 wherein said nucleic acid molecule is administered by a route selected from the group consisting of intramuscularly, intraperitoneally, intradermally, subcutaneously, intravenously, intraarterially, intraocularly, orally, topically, transdermally, intrathecally, intranasally, rectally, vaginally, interurethally, buccally and by inhalation.

36. A method of treating a mammalian subject for a disease comprising the step of administering to cells of said subject, an effective amount of a composition comprising a complex of claim 1 or 2, wherein said polynucleic acid sequence comprises a sequence which encodes a protein or peptide that produces a therapeutic effect on the subject, said protein-encoding sequence under the control of regulatory sequences that direct expression of said protein in the cells of said subject.

37. The method according to claim 36, wherein said nucleic acid molecule is administered by a route selected from the group consisting of intramuscularly, intraperitoneally, intradermally, subcutaneously, intravenously, intraarterially, intraocularly, orally, topically, transdermally, intrathecally, intranasally, rectally, vaginally, interurethally, buccally and by inhalation.

38. A method of treating a mammalian subject for a disease comprising the step of administering to cells of said subject, an effective amount of a composition comprising a complex of claim 1 or 2, wherein said polynucleic acid sequence comprises a sequence which encodes a protein that compensates for a missing, non-functional or partially functioning native mammalian protein, said protein-encoding sequence under the control of regulatory sequences that direct expression of said protein in the cells of said subject.

39. The method according to claim 38 wherein said nucleic acid molecule is administered by a route selected from the group consisting of intramuscularly, intraperitoneally, intradermally, subcutaneously, intravenously, intraarterially, intraocularly, orally, topically, transdermally, intrathecally, intranasally, rectally, vaginally, interurethally and buccally, and by inhalation.

1/3




FIG. 1




FIG. 2

3/3




FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/22841

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------------|
| X | BALLAS-N ET AL: "LIPOSOMES BEARING A QUATERNARY AMMONIUM DETERGENT AS AN EFFICIENT VEHICLE FOR FUNCTIONAL TRANSFER OF TMV-RNA INTO PLANT PROTOPLASTS" BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, vol. 939, 1988, pages 8-18, XP000600715 see abstract see page 13, right-hand column, line 4 - page 14, left-hand column --- -/-- | 1-3, 13, 23-26, 28-31 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 February 1999

Date of mailing of the international search report

12/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 98/22841

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------------------|
| X | BHER J -P: "GENE TRANSFER WITH SYNTHETIC CATIONIC AMPHIPHILES: PROSPECTS FOR GENE THERAPY" BIOCONJUGATE CHEMISTRY, vol. 5, no. 5, 1 September 1994, pages 382-389, XP000465949 see page 383, right-hand column, line 4 - line 12 see page 384; figure 6 | 1-3, 13-17, 23-26, 28-31 |
| A | JUN YOU ET AL: "Surfactant-mediated gene transfer for animal cells" CYTOTECHNOLOGY, vol. 25, 1997, pages 45-52, XP002094013 see abstract | 1-39 |
| A | IRENE VAN DER WOUDE TE AL: "Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 94, February 1997, pages 1160-1165, XP002094014 see abstract see page 1161; figure 1 | 1-39 |
| A | US 5 676 954 A (K. L. BRIGHAM) 14 October 1997 cited in the application see claims 1-21 | 1-39 |
| A | WO 90 11092 A (VICAL INC. ET AL) 4 October 1990 cited in the application see page 45, line 27 - page 47, line 5 see page 53, line 6 - page 54, line 1 | 1-39 |
| A | HARA T ET AL: "EMULSION FORMULATIONS AS A VECTOR FOR GENE DELIVERY IN VITRO AND INVIVO" ADVANCED DRUG DELIVERY REVIEWS, vol. 24, no. 2/03, 17 March 1997, pages 265-271, XP002067903 | 1-39 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 22841

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/22841

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| US 5676954 A | 14-10-1997 | AT 157012 T | 15-09-1997 |
| | | AU 625013 B | 25-06-1992 |
| | | AU 6645690 A | 31-05-1991 |
| | | CA 2044593 A | 04-05-1991 |
| | | DE 69031305 D | 25-09-1997 |
| | | DE 69031305 T | 26-03-1998 |
| | | DK 452457 T | 02-03-1998 |
| | | EP 0452457 A | 23-10-1991 |
| | | EP 0800830 A | 15-10-1997 |
| | | JP 4502772 T | 21-05-1992 |
| | | WO 9106309 A | 16-05-1991 |
| WO 9011092 A | 04-10-1990 | AT 165516 T | 15-05-1998 |
| | | AU 5344190 A | 22-10-1990 |
| | | CA 2049287 A | 22-09-1990 |
| | | DE 69032284 D | 04-06-1998 |
| | | DE 69032284 T | 08-10-1998 |
| | | EP 0465529 A | 15-01-1992 |
| | | EP 0737750 A | 16-10-1996 |
| | | ES 2116269 T | 16-07-1998 |
| | | JP 4504125 T | 23-07-1992 |
| | | US 5703055 A | 30-12-1997 |
| | | US 5580859 A | 03-12-1996 |
| | | US 5589466 A | 31-12-1996 |
| | | US 5693622 A | 02-12-1997 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.